Literature DB >> 28892433

Effects of Education and Income on Treatment and Outcome in Patients With Acute Myeloid Leukemia in a Tax-Supported Health Care System: A National Population-Based Cohort Study.

Lene Sofie Granfeldt Østgård1, Mette Nørgaard1, Bruno C Medeiros1, Lone Smidstrup Friis1, Claudia Schoellkopf1, Marianne Tang Severinsen1, Claus Werenberg Marcher1, Jan Maxwell Nørgaard1.   

Abstract

Purpose Previous US studies have shown that socioeconomic status (SES) affects survival in acute myeloid leukemia (AML). However, no large study has investigated the association between education or income and clinical characteristics, treatment, and outcome in AML. Methods To investigate the effects of education and income in a tax-supported health care system, we conducted a population-based study using individual-level SES and clinical data on all Danish patients with AML (2000 to 2014). We compared treatment intensity, allogeneic transplantation, and response rates by education and income level using logistic regression (odds ratios). We used Cox regression (hazard ratios [HRs]) to compare survival, adjusting for age, sex, SES, and clinical prognostic markers. Results Of 2,992 patients, 1,588 (53.1%) received intensive chemotherapy. Compared with low-education patients, highly educated patients more often received allogeneic transplantation (16.3% v 8.7%). In intensively treated patients younger than 60 years of age, increased mortality was observed in those with lower and medium education (1-year survival, 66.7%; adjusted HR, 1.47; 95% CI, 1.11 to 1.93; and 1-year survival, 67.6%; adjusted HR, 1.55; CI, 1.21 to 1.98, respectively) compared with higher education (1-year survival, 76.9%). Over the study period, 5-year survival improvements were limited to high-education patients (from 39% to 58%), increasing the survival gap between groups. In older patients, low-education patients received less intensive therapy (30% v 48%; adjusted odds ratio, 0.65; CI, 0.44 to 0.98) compared with high-education patients; however, remission rates and survival were not affected in those intensively treated. Income was not associated with therapy intensity, likelihood of complete remission, or survival (high income: adjusted HR, 1.0; medium income: adjusted HR, 0.96; 95% CI, 0.82 to 1.12; low income: adjusted HR, 1.06; CI, .88 to 1.27). Conclusion In a universal health care system, education level, but not income, affects transplantation rates and survival in younger patients with AML. Importantly, recent survival improvement has exclusively benefitted highly educated patients.

Entities:  

Mesh:

Year:  2017        PMID: 28892433     DOI: 10.1200/JCO.2017.73.6728

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  8 in total

1.  Utilization of initial chemotherapy for newly diagnosed acute myeloid leukemia in the United States.

Authors:  Vijaya Raj Bhatt; Valerie Shostrom; Krishna Gundabolu; James O Armitage
Journal:  Blood Adv       Date:  2018-06-12

2.  American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults.

Authors:  Mikkael A Sekeres; Gordon Guyatt; Gregory Abel; Shabbir Alibhai; Jessica K Altman; Rena Buckstein; Hannah Choe; Pinkal Desai; Harry Erba; Christopher S Hourigan; Thomas W LeBlanc; Mark Litzow; Janet MacEachern; Laura C Michaelis; Sudipto Mukherjee; Kristen O'Dwyer; Ashley Rosko; Richard Stone; Arnav Agarwal; L E Colunga-Lozano; Yaping Chang; QiuKui Hao; Romina Brignardello-Petersen
Journal:  Blood Adv       Date:  2020-08-11

3.  Longer distance to specialized treatment centers does not adversely affect treatment intensity or outcomes in adult acute myeloid leukemia patients. A Danish national population-based cohort study.

Authors:  Michael Tøstesen; Mette Nørgaard; Jan Maxwell Nørgaard; Bruno C Medeiros; Claus Werenberg Marcher; Ulrik Malthe Overgaard; Marianne Tang Severinsen; Claudia Schoellkopf; Lene Sofie Granfeldt Østgård
Journal:  Clin Epidemiol       Date:  2019-08-28       Impact factor: 4.790

4.  Are social inequalities in acute myeloid leukemia survival explained by differences in treatment utilization? Results from a French longitudinal observational study among older patients.

Authors:  Eloïse Berger; Cyrille Delpierre; Fabien Despas; Sarah Bertoli; Emilie Bérard; Oriane Bombarde; Pierre Bories; Audrey Sarry; Guy Laurent; Christian Récher; Sébastien Lamy
Journal:  BMC Cancer       Date:  2019-09-05       Impact factor: 4.430

5.  Patient-based prediction algorithm of relapse after allo-HSCT for acute Leukemia and its usefulness in the decision-making process using a machine learning approach.

Authors:  Kyoko Fuse; Shun Uemura; Suguru Tamura; Tatsuya Suwabe; Takayuki Katagiri; Tomoyuki Tanaka; Takashi Ushiki; Yasuhiko Shibasaki; Naoko Sato; Toshio Yano; Takashi Kuroha; Shigeo Hashimoto; Tatsuo Furukawa; Miwako Narita; Hirohito Sone; Masayoshi Masuko
Journal:  Cancer Med       Date:  2019-07-15       Impact factor: 4.452

6.  The prognostic effect of smoking status on intensively treated acute myeloid leukaemia - A Danish nationwide cohort study.

Authors:  Daniel Kristensen; Lars B Nielsen; Anne S Roug; Tove-Christina C Kristensen; Tarec C El-Galaly; Jan M Nørgaard; Claus W Marcher; Claudia Schöllkopf; Kim Theilgaard-Mönch; Marianne T Severinsen
Journal:  Br J Haematol       Date:  2020-04-21       Impact factor: 6.998

Review 7.  Access to Therapy for Acute Myeloid Leukemia in the Developing World: Barriers and Solutions.

Authors:  Luis Antonio Meillon-Garcia; Roberta Demichelis-Gómez
Journal:  Curr Oncol Rep       Date:  2020-10-06       Impact factor: 5.075

Review 8.  The long shadow of socioeconomic deprivation over the modern management of acute myeloid leukemia: time to unravel the challenges.

Authors:  M Joseph John; Philip Kuriakose; Mark Smith; Eve Roman; Sudhir Tauro
Journal:  Blood Cancer J       Date:  2021-08-06       Impact factor: 11.037

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.